Unibest
← Back to patent-cliff list

CAS 109-73-9

1-AminobutaneButylamineMonobutylamine

Codes: (VII)101438-62-a, Tetracaine-016

Application context (from source-drug indications)

Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateAnaesthesiaOxymetazoline Hydrochloride/Tetracaine HydrochloridePeriapical periodontitisOxymetazoline Hydrochloride/Tetracaine HydrochlorideDental cariesOxymetazoline Hydrochloride/Tetracaine HydrochloridePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelAnaesthesiaTetracaine HydrochlorideRetinitis pigmentosaTetracaine HydrochloridePainTetracaine Hydrochloride

Source drugs (routes using this intermediate)

DrugTierExpiry
Paclitaxel/Encequidar mesylateTier C — Watch / trade-
Oxymetazoline Hydrochloride/Tetracaine HydrochlorideTier C — Watch / trade-
PaclitaxelTier B — Position early-
Tetracaine HydrochlorideTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.